The MFN2 Q367H variant reveals a novel pathomechanism connected to mtDNA-mediated

inflammation.

Mashiat Zaman[1], Govinda Sharma[2*], Walaa Almutawa[2*], Tyler GB Soule[3], Rasha Sabouny[2], Matt Joel[3],

Armaan Mohan[2], Cole Chute[2], Jeffrey T Joseph[4], Gerald Pfeffer[5#], Timothy E. Shutt[6#]

[1]Department of Biochemistry & Molecular Biology, Cumming School of Medicine, Hotchkiss Brain

Institute, University of Calgary

[2]Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary

[3]Department of Neuroscience, Cumming School of Medicine, Hotchkiss Brain Institute, University of

Calgary

[4]Hotchkiss Brain Institute, Department of Clinical Neurosciences, Department of Pathology, Cumming

School of Medicine, University of Calgary

[5]Hotchkiss Brain Institute, Department of Clinical Neurosciences; and Alberta Child Health Research

Institute, Department of Medical Genetics, Cumming School of Medicine, University of Calgary

[6]Departments of Medical Genetics and Biochemistry & Molecular Biology, Cumming School of Medicine,

Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, Alberta Children's Hospital Research

Institute; University of Calgary

*Equal contribution

#Corresponding authors

Abstract

Pathogenic variants in the mitochondrial protein MFN2 are typically associated with a peripheral

neuropathy phenotype, but can also include a variety of additional pathologies including myopathy.

Here, we identified a previously uncharacterized MFN2 variant, Q367H, in a patient diagnosed with late-

onset distal myopathy, but without peripheral neuropathy. Consistent with the hypothesis that the

Q367H MFN2 variant contributes to the patient's pathology, patient fibroblasts and transdifferentiated

myoblasts showed changes consistent with impairment of several MFN2 functions. We also observed

mtDNA outside of the mitochondrial network that co-localized with early-endosomes, and measured

activation of both TLR9 and cGAS-STING inflammation pathways that sense mtDNA. Notably, the

inflammatory signaling was increased 3-10 fold in transdifferentiated patient myoblasts. We also found

that re-expressing the Q367H variant in MFN2 knockout cells also induces mtDNA release. As elevated

inflammation can cause myopathy, our findings linking the Q367H MFN2 variant with elevated TLR9 and

cGAS-STING signaling that is exacerbated in myoblasts, can explain patient's myopathy. Thus, we

characterize a novel MFN2 variant in a patient with an atypical presentation that separates peripheral

neuropathy and myopathy phenotypes, and establish a potential novel pathomechanism connecting

MFN2 dysfunction to mtDNA-mediated inflammation.

Introduction

Mitochondria are highly dynamic cellular structures that fuse, divide, move about the cell, and interact with other organelles. The integral outer-mitochondrial-membrane (OMM) proteins Mitofusin1 (MFN1) and Mitofusin 2 (MFN2) mediate fusion of the outer mitochondrial membrane. MFN2, though named for its role in mitochondrial fusion, is also actively involved in several other dynamic processes (1): it mediates contacts between mitochondria and the endoplasmic reticulum (ER) (2), referred to here as mito-ER contact sites (MERCs); is involved in mitochondrial interactions with lipid droplets (3), early endosomes (4), and the nucleus (5); and also plays an active role in mitochondrial autophagy (mitophagy) (6,7).

Impairments in mitochondrial dynamics are linked to genetic neuropathies, with pathogenic variants in MFN2 are typically associated with the axonal peripheral neuropathy Charcot-Marie-Tooth disease subtype 2A (CMT2A)(8). Characterized by weakness, numbness and pain in the distal regions of the body, CMT2A is often an early-onset progressively-worsening disease (9). In addition to peripheral neuropathy, patients with certain MFN2 variants can present with other pathogenic phenotypes, such as myopathy (10–12), optic atrophy, sensorineural hearing loss, ataxia (13), or multiple symmetric lipomatosis (MSL) (14–16). How and why different variants in MFN2 lead mechanistically to pathology is not fully understood, though it is likely not as simple as reduced mitochondrial fusion (17).

In addition to its critical role in neurons, MFN2 is also important for muscle function. Muscle-specific MFN2 knockout (KO) results in muscle atrophy, which is attributed to loss of mitochondrial fusion and subsequent instability of the mitochondrial genome (mtDNA) (18). On top of the depletion of mtDNA copy number that is thought to contribute to respiratory deficiency, mtDNA can accumulate point mutations and deletions in the muscle tissue of these KO mice. A role for MFN2 in maintaining mtDNA is further supported by the fact that certain pathogenic *MFN2* variants show a reduction in mtDNA copy number (19,20) or lead to mtDNA deletions (21). However, highlighting our incomplete understanding of the pathology caused by MFN2 deficiency and the role played by mtDNA, not all pathogenic *MFN2* variants impair mitochondrial fusion, impact mtDNA, or cause respiratory deficiency (17).

Beyond its role of encoding OXPHOS proteins, mtDNA is now also recognized to play an important role as an inflammatory signalling molecule when released from mitochondria (22,23). Examples of inflammatory signalling pathways that detect mtDNA-mediated include TLR9 (4,19), cGAS-STING (24,25) and the inflammasome (26,27). Notably, a recent study showed that inducible muscle-specific loss of MFN1 causes mtDNA release via early endosomes, leading to activation of TLR9/NF-kB

inflammation and myopathy (4). Importantly, pharmacological inhibition of this inflammation improved

the muscle atrophy and physical performance in these mice, implicating sterile inflammation in the

muscle pathology of these mice. Nevertheless, the role of mtDNA-mediated inflammation in the

pathology of pathogenic *MFN2* variants has not been described to date.

Here we report a novel MFN2 variant, Q367H, in a patient diagnosed with late onset distal

myopathy. Functional characterization of patient fibroblasts, transdifferentiated myoblasts and a KO re-

expression cell model reveals mtDNA-mediated inflammation likely explain the patient myopathy, thus

expanding our understanding of the mechanisms by which MFN2 dysfunction contributes to pathology.

Methods

Ethics statement

The patient provided written informed consent for participation in research and consented to

the publication of this report. He was provided with a copy of the draft article prior to submission.

Genetic sequencing and human tissue studies with this participant were part of research protocols

(REB15-2763 and REB17-0850) approved by the Conjoint Health Research Ethics Board at the University

of Calgary.

Exome Sequencing, Variant Confirmation and Sequence Conservation Study

DNA was extracted from blood collected into EDTA tubes using standard protocols. Library

preparation proceeded using the Ion Ampliseq Exome RDY Panel (Thermo Fisher, A38264) according to

manufacturer's protocol. Automated chip loading and templating used the Ion Chef system and 540

chip/chef kit (Thermo Fisher, A30011), and sequencing was performed on an Ion S5 system (Thermo

Fisher, A27212), according to manufacturer's protocols. Base calling, read alignment to hg19, coverage

analysis, and variant calling were performed with Torrent Suite (v. 5.10.1; Thermo Fisher). Similar

analysis can be performed using an alternative bioinformatic pipeline as described previously (28).

Patient VCFs were annotated for predicted variant consequence, gnomAD allele frequency, CADD score,

and OMIM phenotypes, in addition to default parameters with Ensembl's command line Variant Effect

Predictor (VEP). We additionally aligned off-target reads from exome sequencing to identify any mtDNA

variants, as previously described (29).

The variant was verified by Sanger sequencing. Briefly, total genomic DNA was collected using

the E.Z.N.A Tissue DNA Extraction Kit (VWR, CA101319-018). The region of interest was amplified using

PCR with the following primers (F-GAGAAGAGCAGAGAGGCTCTTG and R-ACACAGGGAATCGTGCTGC).

Subsequently the amplified region was sequenced by Sanger sequencing at University of Calgary Centre

For Health Genomics And Informatics.

Amino acid sequence alignment was performed using the T-COFFEE online tool (30). The

sequences were collected from UniProt(31). The following accession codes were used for the sequences:

MFN2: O95140-1, MFN1: Q8IWA4, Mouse MFN2: Q80U63, Fish MFN2: A8WIN6, Chicken MFN2: E1BSH7,

Frog MFN2: Q28CS2, Fruit fly MFN: Q7YU24, Worm MFN: Q23424.

<u>Quantification of Protein Amounts:</u>

Relative quantities were measured using Western Blot Analysis, as previously described (13).

Briefly, cells were lysed with Pierce RIPA buffer (Thermo Scientific™, 89900), and subsequently total

protein was quantified by a BCA assay. 50 µg of protein was loaded from control and patient fibroblasts

on to an SDS-PAGE gel. After running the gel, the blots were transferred to a PVDF membrane overnight.

The blots were probed using the following antibodies: anti-MFN2 (Abnova, H00009927-M03; 1:1000),

anti-MFN1 (Cell Signaling Technology, D6E2S; 1:1000), anti-OPA1 (BD Transduction Laboratories, 612607;

1:1000), anti-Actin (Sigma, A5316; 1:1000). Secondary antibodies complimentary to the primary host

species were used- goat anti-rabbit IgG, HRP linked Antibody (Cell Signaling Technology, 7074S) or goat

anti-mouse IgG-HRP (Santa Cruz Biotechnology, sc-2055). The membranes were visualized with

SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific™, 34095) using the Bio-Rad

ChemiDoc Imaging System. Bands were quantified using Fiji (32).

<u>Cell Culture and Maintenance</u>

Fibroblasts from the patient and healthy individual (age and sex-matched) were generated

through skin biopsies as described (28). The cells were cultured using Minimum Essential Media (Gibco,

11095080), supplemented with 10% Fetal Bovine Serum and 1mM Sodium Pyruvate. Glucose-free

conditions were established using DMEM No Glucose media (Gibco, 11966025), supplemented with

5mM galactose, 10% FBS and 1mM Sodium Pyruvate. Cells were grown in an incubator, maintained at

37^oC and 5% CO_2. For the fatty acid pulse-chase assay, the cells were grown in the glucose media

mentioned above, or glucose-free media with 10% FBS, but no galactose.

WT U2OS and U2OS MFN2 KO cells, a gift from Dr. Edward A Fon (7) (McGill University, Canada),

were grown in DMEM High Glucose Media (Gibco, 11965118) supplemented with 10% FBS. A retrovirus

plasmid containing the MFN2 open reading frame followed by an internal ribosomal entry site and

mitochondria-targeted mNeonGreen was constructed through VectorBuilder (VB230626-1399nzw). A

version of the plasmid with the Q367H variant was generated using in-fusion mutagenesis (Takarabio,

638951). Retrovirus was generated by transfecting Phoenix cells with WT or Q367H plasmids using

Lipofectamine 3000 transfection (ThermoFisher, L3000015). U2OS MFN2 KO cells were then transduced

with retrovirus and cells were sorted for mNeonGreen fluorescence using fluorescence activated cell

sorting (Sony SH800). Endogenous levels of MFN2 expression was confirmed by immunoblotting, and

these stable lines re-expressing either WT MFN2 or the Q367H variant were used for subsequent

analysis.

Mitochondrial Morphology Analysis

Mitochondrial morphology was analyzed by immunostaining as described previously (33), where

30,000 cells were grown in 12mm coverslips for 24 hours and subsequently fixed by 4% PFA for 20

minutes at 37°C. Cells were permeabilized using 0.1% Triton X-100 (MP Biomedicals, J00105) and

blocked using 5% FBS. The OMM protein TOMM20 was chosen to visualize the mitochondrial network,

where cells were incubated with mouse anti-TOMM20 (Santa Cruz Biotechnology, F-10, RRID:

AB_628381) overnight, the subsequently probed with goat anti-mouse secondary conjugated with Alexa

fluor 488 (Thermo Fisher Scientific, A-11029). Cover slips were then mounted on glass slides using

ProLong Diamond Antifade Mountant with DAPI (Invitrogen, P36966).

Oxygen Consumption Rate

The cellular oxygen consumption rate assay for control and patient fibroblasts was performed as

previously described (34). Briefly, 40,000 cells were seeded in wells of the XF-24 plates (Agilent). The

media on the plates was replaced 24 hours later with Seahorse CF Base Medium, supplemented with

1mM Pyruvate, 2mM Glutamine and 10mM Glucose and brought to pH 7.4. Post-incubation for 45

minutes with CO_2, cells were loaded into the Seahorse XF24 Analyzer. Oxygen consumption rates were

measured at three time points, following administration of Oligomycin (0.5 μM), Carbonyl cyanide-p-

trifluoromethoxyphenylhydrazone (FCCP) (1 μM) and Antimycin A (0.5 μM). Following the experiment,

cells in each well were lysed with Pierce RIPA buffer and total protein for each well was quantified with

BCA assays, for normalization purposes.

Measurement of mitochondrial membrane potential:

Fibroblasts were stained with 400 nM TMRE (Sigma-Aldrich, 87917) for 40 minutes, prior to

trypsinization. Cells were then stained using LIVE/DEADTM Fixable Violet Dead Cell Stain kit (Invitrogen,

L34964) re-suspended in PBS prior to acquisition on the cytometer. The cell fluorescence was measured

using a Becton-Dickson FACS CANTO cytometer supported by the BD FACS Diva software (BD Biosciences,

Franklin Lakes, NJ). TMRE signal was detected by a 488 nM laser with a PE-detector, and live/dead signal

was detected by a 405 nM laser with a BV421 detector. Dead cells and doublets were excluded from

analysis. Mitochondrial membrane potential was reported as mean fluorescent intensity (MFI) values of

live, single cells analyzed using Flow-Jo analysis software.

<u>mtDNA and Mitochondrial Nucleoid Analyses</u>

Mitochondrial nucleoids were visualized using confocal microscopy as previously reported (35).

Briefly, 30,000 control and patient fibroblasts were grown on coverslips for 24 hours and fixed with 4%

PFA. Cells were permeabilized with 0.2% Triton X-100 and blocked with 5% FBS. Mitochondrial nucleoids

were labelled using mouse anti-dsDNA antibody (Developmental Studies Hybridoma Bank,

AB_10805293, RRID:AB_10805293) and subsequently visualized using the goat anti-mouse secondary

conjugated with Alexa fluor 488. The mitochondrial network was also labelled using anti-rabbit TOMM20

rabbit anti-TOMM20 (Abcam, ab186735), which was visualized with anti-Rabbit secondary conjugated

with Alexa fluor 647 (Thermo Fisher Scientific, A-21245). Cover slips were mounted using ProLong

Diamond Antifade Mountant with DAPI.

mtDNA copy number analysis was performed using qPCR. Total DNA was collected from control

and patient fibroblasts seeded at the same density. Relative mtDNA copy number was analyzed using

nuclear-encoded housekeeping gene 18S, by amplification using the following primers:

mito-F- CACCCAAGAACAGGGTTTGT

mito-R- TGGCCATGGGTATGTTGTTAA

18S-F- TAGAGGGACAAGTGGCGTTC

18S-R- CGCTGAGCCAGTCAGTGT

For qPCR, 50ng of total DNA was loaded into each well a 96-well plate and the reaction was

performed using the QuantStudio6 Flex Real-Time PCR system (Thermo Fisher Scientific). The delta Ct

method was used to determine the relative copy number.

Long range PCR was done to look for mtDNA deletions using the Takara LA Taq Polymerase

(Takara Bio, RR002M). Total DNA was collected from control and patient fibroblasts and 16.2kBP

fragment was amplified using the following primers- (F- ACCGCCCGTCACCCTCCTCAAGTATACTTCAAAGG

and R- ACCGCCAGGTCCTTTGAGTTTTAAGCTGTGGCTCG). Long Range PCR was done using the following

conditions- (94 °C for 1 min; 98 °C for 10 s, and 68 °C for 11 min (30 cycles), followed by a final extension

cycle at 72 °C for 10 min). The products following the reaction were visualized by gel electrophoresis on a

0.6% gel run for 18 hours at 18V.

<u>Mito-ER Contact Sites</u>

The proximity ligation assay was used to look for MERCs, using the Duolink In Situ Detection kit

(Sigma Aldrich, DUI92008). Briefly, 30,000 control and patient cells were grown on coverslips for 24

hours and subsequently fixed using 4%PFA. Cells were permeabilized with 0.1% Triton X-100 and blocked

using the blocking reagent provided by the kit. The cells were then incubated overnight using mouse-

anti-Calnexin (Sigma-Aldrich, MAB3126) and rabbit anti-TOMM20 (Abcam, ab186735). Following

incubation, PLA probes, complementary to the primary antibodies, anti-mouse (Sigma-aldrich,

DUO92004) and anti-rabbit (Sigma-aldrich, DUO92002) were added to the coverslips. The addition of

DNA ligase and DNA polymerase were subsequently carried out using manufacturer's instructions and

using the reagents provided in the kit. Finally, secondary antibodies anti-mouse secondary conjugated

with Alexa fluor 488 (Thermo Fisher Scientific, A-11029) and anti-Rabbit secondary conjugated with

Alexa fluor 647 (Thermo Fisher Scientific, A-21245) were added for visualizing the ER and mitochondrial

networks respectively. The coverslips were mounted with ProLong Diamond Antifade with DAPI before

imaging.

<u>Lipid Droplets and Fatty Acid Pulse-Chase</u>

Total cellular lipid droplets were labelled using HCS LipidTox Green (Thermo Fisher Scientific,

H34350), following the same immunostaining protocol to label the mitochondrial network, except for

using 0.1% Saponin (Sigma Aldrich, SAE0073-10G) as the permeabilizing solution. The mitochondrial

network was also labelled using anti-rabbit TOMM20 rabbit anti-TOMM20 (Abcam, ab186735), which

was visualized with anti-Rabbit secondary conjugated with Alexa fluor 647 (Thermo Fisher Scientific, A-

21245).

For the fatty acid pulse-chase assay, 50,000 cells were seeded on a 35mm glass bottom dish with

20mm indented imaging region. Cells were grown for 24 hours, after which they were pulsed with the

fluorescent fatty acid precursor BODIPY 558/568 C_{12} (Invitrogen, D3835). After 24 hours incubation with

the BODIPY, cells were incubated with either glucose or glucose-free media and chased at time points 0

hours, 6 hours and 24 hours following the addition of the two media conditions. When the variable

media conditions were added, MitoTracker Green (Invitrogen, M7514) was also added at 50nM

concentration for visualizing the mitochondrial network.

<u>Mitochondria, mtDNA and Early Endosome Imaging</u>

The triple staining of the mitochondrial network, mtDNA and early endosomes was performed

using sequential immunostaining. The steps until blocking are the same as described above for the

mitochondrial network. Following blocking, primary antibodies were added for the mtDNA (same as

above) and mitochondrial network (same as above) and secondary antibodies were added accordingly-

anti-mouse secondary conjugated with Alexa fluor 488 (Thermo Fisher Scientific, A-11029) and anti-

Rabbit secondary conjugated with Alexa fluor 568 (Thermo Fisher Scientific, A-11004). Following

secondary antibody incubation, coverslips were thoroughly washed with PBS and the primary antibody

to label early endosomes was added rabbit anti-RAB5 (Cell Signaling Technology, 3547T). Subsequently,

the complementary secondary antibody anti-Rabbit secondary conjugated with Alexa fluor 647 (Thermo

Fisher Scientific, A-21245) was added. The coverslips were mounted using ProLong Diamond Antifade

mounting media.

<u>Fibroblast Transdifferentiation</u>

The coding sequence for human myoD1 (accession NM_002478) was PCR amplified from a

human skeletal muscle cDNA library and subcloned into pWPXL (pWPXL was a gift from Didier Trono

(Addgene plasmid # 12257) in place of eGFP at the 5'BamHI and 3'EcoRI restriction sites. The DNA

sequence was confirmed using Sanger DNA sequencing.

Lentivirus production was performed using 293FT cells grown to 90% confluency on five, 15 cm^2

cell culture plates, by cotransfecting 112.5 µg pWPXL-myoD1, 73 µg psPAX2 and 39.5 µg pMD2.G [gifts

from Didier Trono (Addgene, plasmid # 12260) using PEIpro transfection reagent (Polyplus). The cell

culture media was collected 48 hours post-transfection, quantified using Lenti-X^{TM} GoStix^{TM} Plus (Takara

Bio USA, 631280), centrifuged at 500xg for 5 min, 0.45 um filtered and stored at -80°C as 5 mL aliquots.

Non-immortalized primary fibroblasts below passage 5 were grown at 37°C, 5% CO_2 in complete

media: DMEM – high glucose (Corning, 10-013-CV), 10% FBS (Corning, 35-077-CV), 1% P/S (VWR, K952).

T75s or 24 well plates were coated in 0.1 mg/mL VitroCol Type I human collagen (Advanced BioMatrix,

5008) for 1 hour before gently washing with PBS. Cells were seeded at 6,300/cm^2 and transduced at 75%

confluency. 5 µg/mL polybrene (Sigma-Aldrich, TR-1003-G) was mixed with MYOD1 lentivus at GoStix

Values of either 11,500 or 12,000 depending on the biological replicate. Cells were transduced by

spinfection, specifically a one-hour spin at 800 xg, RT, and then lentiviral supernatant was replaced with

complete media. Media was changed every two days and cells were allowed to transdifferentiate for 7

days before fixing or RNA extraction. Conversion to myoblasts was confirmed by visualization of Desmin

using Desmin (D93F5) XP Rabbit mAb (CST, cat. #5332S) and secondary AlexaFluor 594 chicken anti-

rabbit (Invitrogen, A-21442). RNA for qPCR was extracted using RNeasy Mini Kit (QIAGEN, 74104).

<u>Analysis of TLR9-NF-kB Signalling Pathways:</u>

The expression of genes associated with the TLR9-NF-kB was analyzed by RT-qPCR. The TLR9

inhibitor Chloroquine (MilliporeSigma, C973P63) and the cGAS-STING inhibitor Ru.521 (Aobious,

AOB37877) were added to the cell culture media (final concentration 1uM) for 24 hours, and

subsequently the cells were washed five times with PBS. Briefly, total RNA was extracted from cells using

the HP Total RNA Extraction Kit (VWR, CA101414-852), according to the manufacturer's instructions. The

collected RNA was reverse transcribed using the iScript Advanced cDNA Synthesis Kit (BioRad, 1725038).

Subsequently, qPCR was performed using the QuantStudio 6 Real-Time PCR system (Thermo Scientific).

The primers used for amplification of target genes are:

Beta Actin- F- AAGACCTGTACGCCAACACA

Beta Actin- R- AGTACTTGCGCTCAGGAGGA

Asc-F- CATGAACTGATCGACAGGATG

Asc-R- GGACCTCCTCCAAATGTTTC

IL6-F-- AGACAGCCACTCACCTCTTCAG

IL6-R- TTCTGCCAGTGCCTCTTTGCTG

Nlrp3-F- GCTGGCATCTGGATGAGGAA

Nlrp3-R- GTGTGTCCTGAGCCATGGAA

S100a9-F- GGAATTCAAAGAGCTGGTGC

S100a9-R- TCAGCATGATGAACTCCTCG

TNF-F- GCCCATGTTGTAGCAAACCC

TNF-R- GGAGGTTGACCTTGGTCTGG

IFN-α-F- AAATACAGCCCTTGTGCCTGG

IFN-α-R- GGTGAGCTGGCATACGAATCA

IFN-β-F- AAGGCCAAGGAGTACAGTC

IFN-β-R- ATCTTCAGTTTCGGAGGTAA

<u>Imaging and Analyses</u>

All imaging was performed as previously described (24). The Olympus Spinning Disk Confocal

System (Olympus SD OSR) was used with the UAPON 100XOTIRF/1.49 oil objective lens. For live cell

imaging, a cellVivo incubation module was used to maintain cells at 37°C and 5% CO_2. For analysis of

mitochondrial branch length and footprint, the MiNA plugin (36) was used on Fiji. Number and size of

PLA puncta, mitochondrial nucleoids, lipid droplets and endosomes were performed using the particle

analysis tool on Fiji, following thresholding. All co-localization studies were performed using the JaCoP

plugin (37) on Fiji. Extra-mitochondrial mtDNA nucleoids were quantified using the mitoQC plugin on FIJI

(38), setting the mtDNA as 'red' signals and mitochondria as 'green' signals. Mito-endosome distances

were calculated by quantifying average linear distance between respective signals. All quantitative

figures and statistical tests were performed using GraphPad Prism 9.

 Results

Patient Report, Whole Exome Sequencing and Protein Expression for MFN2 Q367H Variant

A male patient in their 70s years presented with a two-year history of slowly progressive

weakness affecting his lower extremities. Initial symptoms included difficulty walking uphill, and he

eventually developed difficulty with stairs and limitations with walking on the ground level and rising

from a chair. There were no cramps, fasciculations, or contractures. No sensory loss or coordination.

Dysarthria, dysphagia, ptosis, or diplopia were not present.

The patient was medically well and did not have any history of cardiac disease. The parent of the

proband developed weakness in her lower legs in her 60s, with progressive limitations in her mobility.

Apparently, she was diagnosed with CMT disease, but her clinical profile was not available for review.

The parent died in her early 80s due to congestive heart failure. The parent's two siblings aged 86-80,

and her other two children of ages 40-45 were all unaffected. Clinical examination of the patient

demonstrated a cognitively normal individual. Cranial nerve examination was normal. Motor

examination revealed MRC grade 4+ strength for ankle dorsiflexion and 4+ plantarflexion bilaterally.

Proximal and axial muscle testing was normal, except for Achilles tendon reflexes. The sensory

examination was normal. Creatine kinase enzyme activity was elevated to a maximum of 455 U/L

(reference range ≤ 195 U/L). The muscle biopsy showed necrotic and regenerating myofibers, myofiber

hypertrophy, excessive endomysial and perimysial fibrosis, and extensive infiltration by adipose tissue.

Immunostaining for dystrophin, alpha/gamma sarcoglycan, spectrum, α-laminin, desmin, and α-β-

crystallin was unremarkable (Figure 1A). There was no inflammatory cell infiltrate. For the magnetic

resonance imaging (MRI) examination, upper and lower legs revealed fatty infiltration of the adductor

longus gluteus minimus, tibialis anterior, and inferior gastro-soleus bilaterally (Figure 1G/H).

The case was interpreted as a chronic myopathy with nonspecific muscle pathology. A genetic

cause was suspected given the family history of a similar condition in his parent, and lack of

inflammation on muscle biopsy. Clinical testing with a gene panel encompassing 200 genes associated

with myopathy, neuropathy, and neuromuscular disorders identified a previously uncharacterized

heterozygous variant in the *MFN2* gene, c.1101G>C, p. (Gln367His) [Table 1/Figure 2A]. Research based

exome sequencing again identified the MFN2 variant, as well as heterozygous variants of unknown

significance in *SYNE1* and *DYSF* (Table 1). While pathogenic variants in *SYNE1* can be associated with

autosomal dominant neuromuscular disease, this patient variant was not considered to be clinically

relevant for the following reasons: (a) the variant is not in the same domain as pathogenic variants

previously associated with autosomal dominant disease, (b) *SYNE1* variants in this region of the gene

have only been associated with autosomal recessive disorders, while our patient is heterozygous, (c) no

characteristic nuclear abnormalities associated with pathogenic variants in *SYNE1* (39) were observed in

patient fibroblasts under microscopy, (d) the myopathy phenotype is not in keeping with the *SYNE1*-

related disease phenotype, which includes proximal weakness and contractures. Meanwhile, the *DYSF*

variant was not considered to be an explanation for this patient's disease because it is a single

heterozygous variant in a condition caused by biallelic variants in DYSF, and we are not aware of any

reports of dysferlinopathy associated with only a single pathogenic variant. Thus, based on strong

suspicion for the relationship between the MFN2 variant and the patient phenotype, we proceeded with

the studies described in this report using patient fibroblast cells.

Characterization of Patient Fibroblasts:

To investigate if the Q367H variant contributes to the patient phenotype, we began by examining

skin fibroblasts obtained from the patient. Immunoblotting for mitochondrial fusion proteins revealed no

significant changes in the expression of MFN2, MFN1, or the inner mitochondrial membrane fusion

protein OPA1 (Figure 2C-G). Next, to determine if this MFN2 variant may contribute to the pathology and

to gain potential insight into the disease mechanism(s), we characterized patient fibroblasts for

alterations to a variety of MFN2-mediated functions.

Mitochondrial Network Morphology and Respiration in MFN2 Q367H Fibroblasts

First, as fibroblast cells from CMT2A patients with MFN2 variants sometimes have fragmented

mitochondria (17), we examined mitochondrial morphology as a potential downstream readout of

altered mitochondrial fusion (Figure 3A-C). No changes were observed under standard culture

conditions. However, glucose-free growth conditions supplemented with galactose, which forces cells to

use mitochondria for energy rather than glycolysis, can be used detect morphology changes in

fibroblasts from patients with MFN2 variants (40). Consistent with decreased mitochondrial fusion and

mitochondrial dysfunction, Q367H patient fibroblasts grown in glucose-free galactose-supplemented

media showed a marked increase in the number of cells with fragmented mitochondrial networks, as

well as a decrease in average mitochondrial length. Impairment of mitochondrial function in patient

fibroblasts was further reinforced by functional studies of oxygen consumption. Patient fibroblasts had

increased basal oxygen consumption but reduced maximal oxygen consumption (Figure 3D). We also

measured mitochondrial membrane potential using TMRE, but did not observe and significant

differences in between control and patient cells (Figure 3E). As mitochondrial fragmentation alone does

not indicate MFN2 dysfunction (*e.g.*, reduced mitochondrial health in general can lead to mitochondrial

fragmentation), we also explored other functions performed by MFN2 to provide additional evidence for

MFN2 dysfunction.

Perturbated Mitochondrial Nucleoids in MFN2 Q367H Patient Fibroblasts

Mitochondria house their own genome, mtDNA, which is present in hundreds of copies

throughout the mitochondrial network and is organized into nucleoid structures. As mtDNA nucleoids

can be altered by impairments to mitochondrial fusion (41), we sought to examine mtDNA in Q367H

patient fibroblasts (Figure 4A/B). Similar to mitochondrial morphology, there were no changes to mtDNA

nucleoid size or abundance in standard media. However, under glucose-free galactose-supplemented

conditions, patient fibroblasts had a decrease in the average number of mitochondrial nucleoids per cell,

while the average nucleoid size was increased (Figure 4A/C). Of note, in both growth conditions, a small

number of mtDNA nucleoids were observed outside the mitochondrial network in patient fibroblasts

(circled in Figure 4A). Meanwhile, the mtDNA copy number did not change under any conditions (Figure

4D/E), nor were any mtDNA deletions detected (Figure 4F). Observing fewer, larger nucleoids without

changes in mtDNA copy number is likely due to nucleoid clustering, a phenotype often observed with

impaired mitochondrial fusion (41). As such, the mtDNA studies are consistent with reduced fusion

leading to mitochondrial fragmentation in the Q367H cells when grown in glucose-free galactose-

supplemented media.

MFN2 Q367H Fibroblasts show reduced number of Mito-ER Contact Sites

MFN2 also mediates mito-ER contact sites (MERCs) (42). As an estimate of MERCs, we used a

proximity ligation assay to detect regions where the mitochondria and ER are within ~40 nm. Co-

localization analysis of the PLA signal with either mitochondrial or ER (Supplemental Figure 1) was used

to validate the PLA signal as representative of MERCs. No absolute changes in the number or size of the

PLA signals were observed in standard media. However, under glucose-free conditions, Q367H cells had

fewer PLA puncta, though these puncta were slightly larger (Figure 5A-C). As changes in MERCs could be

due to global changes in mitochondrial abundance, we also measured the area of mitochondria

(mitochondrial footprint). Importantly, we do not observe significant differences between mitochondrial

footprint in control and patient cells (Figure 5D). However, when the MERC PLA signal is normalized to

the mitochondrial footprint, we see a slight a reduction in the number of MERCs in the patient

fibroblasts in standard conditions, which is further exaggerated under glucose-free conditions (Figure

5E). Together, these data indicate perturbations in MERCs in the Q367H fibroblasts that are consistent

with MFN2 dysfunction.

Dysfunction in Mitochondrial Fatty Acid Import Leads to Lipid Droplet Accumulation in Patient

Fibroblasts

Given the role of MFN2 in mediating mitochondria-lipid droplet interactions, and the fact that

lipid droplets are altered in fibroblasts from patients with MFN2 variants (17), we next explored lipid

droplets in the Q367H fibroblasts. Interestingly, we see a significant increase in the number and size of

cellular lipid droplets in patient fibroblasts, both grown in standard and glucose-free galactose-

supplemented media (Figure 6A-D). To explore the mechanism underlying the increased accumulation of

lipid droplets, we examined lipid transfer from lipid droplets to mitochondria using an assay that takes

advantage of the BODIPY 558/568 fatty acid precursor (43). In this assay, the fluorescently labelled lipid

is loaded into lipid droplets during a 24-hour incubation, and its transfer to mitochondria can be

monitored over time by microscopy. In control cells in standard conditions, some fatty acid pre-cursor

transfers into the mitochondrial network (Figure 6E-F), with higher transfer under glucose starvation

conditions (without galactose supplementation). Notably, in patient fibroblasts, no fatty acid trafficking

from lipid droplets to mitochondria is observed under either growth condition (Figure 6E-F). These

findings suggest that the excess lipid droplets seen in the patient fibroblasts are due to an accumulation

of lipids due to a lack of fatty acids transfer from lipid droplets to mitochondria.

MFN2 Q367H Patient Cells Show mtDNA-Mediated Inflammation

Following up on observation of nucleoids outside of the mitochondrial network (Figure 4), we

looked for evidence of mtDNA-mediated inflammation, which is linked to impaired mitochondrial fusion

and can cause myopathy (4). First, to look for signs for an inflammatory response, we examined the

expression of several inflammation genes via q-RT-PCR. Notably, even when cells were grown in standard

glucose conditions, we observed an elevation of genes that mediate TLR9 signalling (*i.e.*,

ASC/NLRP3/S100A9) and downstream cytokines of the TLR9 pathway (*i.e.*, IL6/TNFα), as well as genes

downstream of the cGAS-STING pathway (INF-α/β) (Figure 7A). Similar inflammatory signalling was

observed when fibroblasts were grown in galactose media (Supplemental Figure 2). To determine if the

increased expression of these genes was due to the TLR9 or cGAS-STING signalling pathways, fibroblasts

in standard media were treated with chloroquine to inhibit TLR9 signalling (44), or RU.521 (45) to inhibit

cGAS (Figure 7A). Strikingly, chloroquine reduced TLR9 targets, while RU.521 reduced cGAS-STING

targets. The fact that each treatment significantly reduced expression of the relevant genes to the levels

seen in the control patient fibroblasts, confirms that both TLR9-NF-kB and cGAS-STING signalling are

elevated in the patient fibroblasts and that these are the primary pathways driving inflammation.

Given the link to TLR9 signalling, which detects mtDNA in endosomes, we also looked to see if

mtDNA outside the mitochondrial network colocalized with Rab5C-labelled early endosomes.

Remarkably, we observed co-localization of extra-mitochondrial mtDNA with early endosomes, including

enlarged endosomes harbouring several mtDNA nucleoids (Figure 7B-C). Overall, these findings point to

a mtDNA-mediated sterile inflammatory response, mediated through localization of mtDNA into early

endosomes and the cytosol (Figure 7D).

MFN2 Q367H Patient Transdifferentiated Myoblasts Show Elevated Inflammation, Disrupted MERCs

and Reduced mtDNA Nucleoid Content

To examine the cellular and inflammatory phenotypes more closely in a relevant cell type, we

transdifferentiated control and patient fibroblasts into myoblasts for additional characterization. Upon

transdifferentiating, we still observed increased inflammatory signalling (Figure 8A). However, compared

to fibroblast cells, patient myoblasts exhibited an additional 3-fold increase in cGAS-STING interferons,

and a 10-fold increase in the TLR9 inflammatory signalling, indicating that these pathways are even more

strongly activated in patient muscle cells. Finally, we examined some basic parameters of MFN2

functions in our transdifferentiated patient myoblasts. First, we found no changes in gross mitochondrial

morphology or the average length of mitochondrial branches in patient myoblasts (Figure 7B-C). Second,

patient myoblasts had fewer MERCs, which were also smaller in size (Figure 8D-F). Finally, the mtDNA

nucleoid analysis found a reduction in the number nucleoids per cell in patient myoblasts, as well as a

decrease in size of the nucleoids (Figure 8G-I). Notably, consistent with findings in patient fibroblasts, a

subset of these nucleoids could be found outside of the mitochondrial network.

Re-Expression of MFN2 Q367H in MFN2 KO Cells Recapitulates mtDNA Release Phenotype

To determine if the MFN2 Q367H variant is sufficient to induce the mitochondrial alterations

that we observed in patient fibroblasts, we re-expressed either WT MFN2 or the Q367H variant in U2OS

MFN2 KO cells (Figure 9)(Supplemental Figure 3). As MFN2 overexpression can induce artefacts (46), we

first confirmed that MFN2 was expressed at endogenous levels (Figure 8B). Validating our KO re-

expression approach, we found that WT MFN2 re-expression restored all the phenotypes we observed in

the U2OS KO cells (Figure 9) (Supplemental Figure 3). In line with the normal mitochondrial morphology

observed in patient fibroblasts grown in glucose and myoblasts, the mitochondrial network in the Q367H

re-expression cells was also restored (Figure 9A,C), further suggesting this variant is competent for

mitochondrial fusion. With respect to the number and size of mtDNA nucleoids, the Q367H re-

expression cells fell between the extremes in the WT and MFN2 KO cells (Supplemental Figure 3A,B).

Next, we focused on the unique mtDNA release phenotype seen in the Q367H patient cells. Despite the

ability of the Q367H variant to restore mitochondrial morphology, and consistent with our earlier

observations in patient cells harboring the Q367H variant, there was a prominent presence of mtDNA

outside the mitochondrial network in the U2OS MFN2 KO cells re-expressing Q367H (Figure 9A)

(Supplemental Figure 3C), and this mtDNA was predominantly co-localized with endosomes (Figure 9C)

(Supplemental Figure 3D,E). Intriguingly, there were significant differences between MFN2 KO and the

Q367H re-expression lines with respect to mtDNA release. For example, while there was slightly more

extra mitochondrial mtDNA in U2OS KO cells, only about half of the mtDNA co-localized with endosomes

in the MFN2 KO cells (Supplemental Figure 3C-E). Moreover, compared to MFN2 KO cells, endosomes in

the Q367H re-expression cells were more abundant, larger, and on average closer to mitochondria

(Supplemental Figure 9F-H). Overall, these findings show that while the Q367H variant is competent for

mitochondrial fusion, it is sufficient to cause mtDNA release, and that mtDNA/endosome colocalization

and endosome phenotypes are exacerbated with the Q367H variant compared to the MFN2 KO cells.

Discussion:

We report an individual with a late-onset myopathy phenotype and a previously uncharacterized

variant in *MFN2*. We pursued the investigations described in this report based on strong clinical

suspicion for this as a potential pathogenic variant. This sequence change in *MFN2* replaces glutamine

with histidine at codon 367 of the MFN2 protein (Q367H). The glutamine residue is highly conserved,

and there is a small physicochemical difference between glutamine and histidine, implying a

hypermorphic change. The MFN2 Q367 amino acid is conserved across vertebrate MFN2 sequences, as

well as with the MFN1 paralogue (Figure 2B). The MFN2 Q367H variant is present in population

databases with a very low allele frequency (highest allele frequency 0.000242 in Gnomad according to

dbSNP report rs373211062, accessed June 4, 2024), including one homozygous individual. The variant

has an entry in Clinvar (439898, accessed June 4, 2024) and is classified as having conflicting

interpretations of pathogenicity, with 4 entries from clinical testing of patients with neurological

phenotypes. In a large cohort study, a patient with early onset peripheral neuropathy was reported who

was compound heterozygous for Q367H and P184R MFN2 variants (47). However, the

Q367H MFN2 variant has not been functionally characterized, or previously reported in the literature as

a standalone disease-causing variant. The family history of the patient's parent suggests autosomal

dominant inheritance, which is in keeping with this variant, although confirmation of this variant was not

possible in the parent. Furthermore, a different amino acid substitution at this position (Q367P) was

associated with a neuropathy presentation (48), providing additional support that variants at this

position are likely to be associated with this disease. All considered, the Q367H variant is highly plausible

as a reduced penetrance pathogenic variant given its extremely low frequency in population databases,

its prevalence in individuals with neurological phenotypes, its presence in published cases from

literature. The data from studies in this report point to the deleterious nature of the Q367H variant, and

importantly demonstrate the damaging effect of this variant in cells transdifferentiated to the muscle

lineage.

This case illustrates many of the challenges when conducting research with people affected by

genetic conditions with very late onset. Information from control population databases may be

misleading if individuals are presymptomatic for a very late onset disease, or when phenotypes are very

mild and slowly progressive. Even for paediatric-onset disease, pathogenic variants appear in a

substantial proportion of control individuals (2.8% in one study) (49) , and this number may be

comparable or even higher for very-late onset disorders, such as the one described in this report. Future

research will improve our understanding of genetic variants and disorders with very late onset and

variable penetrance, but identification and investigation of cases is difficult since they may be mistaken

for degenerative or acquired conditions (for example, prior work showing diagnoses of genetic spastic

paraplegia in patients initially diagnosed with sporadic primary lateral sclerosis)(50). Other factors

include the lack of availability of family members for segregation of variants (i.e: parents have expired by

the time the patient is diagnosed, or family members are estranged, or the disease status is not yet

known for younger family members). In this respect, we acknowledge the limitations of this study, which

only includes a single affected participant. However, we hope to bring attention to the fact that the

investigation of genetic disorders is important to our broader understanding of genetic diseases and

operates with the above-mentioned special challenges. Furthermore, our findings from the re-

expression of the variant in a KO cell line show the importance of functional characterization to confirm

potential pathogenic variants.

Despite the fact that over 150 MFN2 variants have been reported in patients with CMT2A, we

still do not have a complete understanding of how MFN2 dysfunction contributes to disease. The

situation is complex, as MFN2 has multiple functions in the cell, and CMT2A can have additional

pathological phenotypes beyond peripheral neuropathy. Moreover, only a handful of MFN2 variants have

been characterized functionally, and even then, often only for one or two of MFN2's known functions

(17). Thus, a better understanding of how MFN2 variants affect MFN2 functions is essential to

understanding how MFN2 contributes to disease. Here, our characterization of cells from a patient

exhibiting distal myopathy who carried the candidate pathogenic MFN2 Q367H variant provides novel

mechanistic insight into MFN2-mediated pathology. The fact that several MFN2-mediated functions are

impaired in the patient cells, especially when they are forced to use mitochondria for energy production,

supports the notion that the Q367H variant impairs MFN2 function and likely contributes to the patient

pathology. Moreover, to our knowledge, the association of mtDNA release and inflammation with an

MFN2 variant has not been reported previously, and supports a mechanistic pathway by which MFN2

dysfunction contributes to inflammation. Finally, the elevated levels of inflammation in patient-derived

transdifferentiated myoblasts further support a novel disease pathomechanism for MFN2-mediated

inflammation driving myopathy.

Several lines of evidence support the pathogenicity of the Q367H MFN2 variant. Patient

fibroblasts show perturbation to multiple functions performed by MFN2, including mitochondrial fusion

mtDNA nucleoid distribution, MERCs and cellular lipid droplets. Similarly, characterization of our Q367H

re-expression line also provides direct evidence that this variant is not fully functional. With respect to

mitochondrial fusion, similar to our findings, several MFN2 variants do not show mitochondrial

fragmentation when grown in standard glucose conditions (17). However, culturing fibroblasts in

galactose can reveal fragmentation of the mitochondrial network, as reported for MFN2 D210V (10), and

as we see for the Q367H variant. This network fragmentation could be caused by reduced fusion and/or

increased fission, which can occur in response to a variety of stimuli (51). Given the well-defined role of

MFN2 in mitochondrial fusion, the fragmentation is consistent with reduced fusion. Meanwhile, as

reduced mitochondrial fusion can also impact mtDNA distribution (41), the changes we see in

mitochondrial nucleoids are also consistent with reduced fusion in patient fibroblasts when grown in

galactose. Nevertheless, the Q367H re-expression line shows that this variant can restore mitochondrial

morphology in MFN2 KO cells. Thus, any impairment in mitochondrial fusion is likely to be minor, and

only noticeable under conditions such as when grown in galactose.

Beyond mitochondrial fusion, perhaps the best characterized function of MFN2 is in regulating

MERCs (2). Notably, MERCs in fibroblasts from patients with various *MFN2* variants can show a variety of

changes (17), and the reduction in the number and size of MERCs that we observed in patient cells is

consistent with MFN2 dysfunction. Intriguingly, altered MERCs could contribute to the patient myopathy,

as pathogenic variants in *SEPN1*, another gene implicated in MERC biology, also causes a myopathy

phenotype (52).

Also consistent with MFN2 dysfunction and in line with our findings, an increased number and

size of lipid droplets in fibroblasts is reported in fibroblasts patients with other MFN2 variants (53), as

well as upon MFN2 depletion (3). Intriguingly, the lipid droplet phenotype is evident in standard growth

conditions when mitochondrial morphology was unaltered. Notably, the mechanism by which impaired

MFN2 function leads to increased size and abundance of lipid droplets in patient fibroblasts has not

been investigated previously. We envision several possible explanations: decreased transfer of lipids into

mitochondria from lipid droplets, or increased transfer of lipids from mitochondria to lipid droplets. Our

finding that patient fibroblasts failed to import fatty acids into mitochondria, even under glucose

starvation conditions, is in line with the first possibility, and likely reflects the role of MFN2 in mediating

mitochondria-lipid droplet interactions (54). Though we expect reduced lipid transfer will also explain

the increased lipid droplet accumulation observed in fibroblasts from patients with other MFN2 variants,

this remains to be determined.

Characterization of the transdifferentiated patient myoblasts provides further evidence of MFN2

dysfunction and important insight into the muscle myopathy phenotype in the patient. Consistent with

MFN2 dysfunction, we see a significant decrease in the number and size of mitochondrial nucleoids, as

well as fewer and smaller MERCs in transdifferentiated patient myoblasts. However, we did not observe

any changes in mitochondrial network morphology. Notably, the transdifferentiated myoblasts were

grown in standard myoblast media, as opposed to the glucose-free galactose-supplemented media

required to elicit differences in the patient fibroblasts. Other differences in growth conditions between

transdifferentiated patient myoblasts (*e.g.*, collagen matrix), or the inherent differences between

fibroblast and myoblast cell types may also explain differences between patient fibroblasts and

transdifferentiated myoblasts. Regardless, the reduced number of nucleoids in the patient cells is

consistent with MFN2 dysfunction, as muscle-specific loss of MFN2 leads to mtDNA depletion (18).

The finding of mtDNA release and inflammation in both Q367H patient fibroblasts and

transdifferentiated myoblasts is novel in the context of pathogenic MFN2 variants and is likely relevant to

disease mechanism. The mtDNA release and endosome co-localization also observed in the Q367H re-

expression cells further shows that this variant causes mtDNA release, rather than an undetected

difference in the genetic background of the patient. With respect to the inflammatory signals, the fact

that inhibitors of both TLR9/cGAS-STING pathways lead to decrease in their downstream cytokines,

indicates that both pathways are activated. These findings are also consistent with previous work on

impaired mitochondrial fusion and increased inflammation. With respect to MFNs, a recent paper by

Irazoki *et al.*, found that knockdown of either MFN1 or MFN2 in myoblasts could promote TLR9 signalling

(4). Arguing that activation of TLR9-mediated inflammation is a general response to loss of mitochondrial

fusion, loss of the inner mitochondrial membrane fusion protein OPA1 in muscle leads to TLR9-mediated

NF-κB activation (but not cGAS-STING), where it also drives an inflammatory myopathy (55). Thus, it

seems that loss of fusion is sufficient to induce mtDNA-mediated TLR9 inflammation in muscle cells that

can drive myopathy. A mechanism that may explain the phenotype of the patient harbouring the Q367H

variant. Meanwhile, the increased cGAS-STING signalling that we also see in Q367H patient cells is

consistent with increased cGAS-STING activity also reported in MFN2-deficient myoblasts (4), as well as

in microglia where MFN2 is downregulated (56). Whether cGAS-STING signalling further perturbs

pathology remains to be determined, though elevated cGAS-STING inflammation is also linked to

myopathy (57).

Another interesting question involves how MFN2 loss of function drives mtDNA release to

stimulate both TLR9 and cGAS-STING inflammation. In this regard, several recent studies are relevant to

endosomal-mediated mtDNA release (58–60). A model seems to be emerging where, in the context of

stalled mtDNA replication intermediates, enlarged nucleoid clusters are transferred directly into early

endosomes, where the mtDNA can be detected by TLR9. When this quality control pathway is

overwhelmed, it can lead to release of mtDNA from endosomes into the cytosol, and cGAS-STING

activation (60). Notably, one mechanism by which loss of mitochondrial fusion is proposed to impact the

mtDNA is through imbalanced distribution of mtDNA maintenance proteins (61), which may lead to an

increased abundance of stalled mtDNA replication intermediates. Thus, mtDNA replication fork stalling in

response to impaired mitochondrial fusion may trigger initial mtDNA release into endosomes, and the

subsequent TLR9 activation associated with MFN2 dysfunction. The fact that we see extra mtDNA and

inflammatory signalling in patient cells with normal mitochondrial morphology (*e.g.*, fibroblasts grown in

standard media, and differentiated myoblasts), suggests that even subtle alterations in mitochondrial

fusion are sufficient to impact the mtDNA. Alternatively (or in conjunction), the differences in MERCs,

which can demarcate sites of mtDNA replication (62,63), could also impair mtDNA replication and trigger

to mtDNA release into endosomes.

Meanwhile, as elevated cGAS-STING is not found with MFN1 or OPA1 depletion (4,55,64), the

elevated cGAS-STING signalling in myoblasts devoid of MFN2 (4), and seen here in MFN2 Q367H patient

cells, suggests another role for MFN2 in mediating mtDNA release beyond just reduced mitochondrial

fusion. In this regard, MFN2 can interact with RAB5C on early endosomes (4). As such, it is tempting to

speculate that MFN2 has a role in mediating the mitochondrial-endosome interactions required for

endosome-mediated removal of stalled mtDNA replication intermediates, and that altering this

interaction promotes mtDNA escape into the cytosol to activate cGAS-STING inflammation. In this

regard, the differences between MFN2 KO and Q367H re-expression cells with respect to endosomal

mtDNA and endosome alterations support the notion that the Q367H variant is not just 'loss of function'

with respect to mtDNA release. Future studies examining the mechanisms of mtDNA release will likely

provide more insight to the role played by MFN2 and may benefit from examining the Q367H variant as a

means to perturb MFN2 function.

It is worth noting that MFN2 could also influence inflammation through its other functions. For

example, there are connections between disrupted MERCs and activation of sterile inflammation,

particularly in high energy-demanding tissues such as the heart (65). Meanwhile, relevant to the

increased lipid droplet abundance associated with MFN2 dysfunction and seen even in standard growth

conditions with normal mitochondrial morphology, it is notable that lipid droplet biology intersects with

inflammation. Specifically, elevated lipid droplet abundance correlates with increased inflammation (66–

69). Overall, our findings are consistent with MFN2 dysfunction contributing to inflammation, which is a

possible explanation for myopathy initially described in the proband.

The patient presentation, with late onset myopathy, but without neuropathy, offers a unique

opportunity to separate the pathological outcomes of MFN2 dysfunction by examining the specific

mechanism leading to myopathy. Although myopathy has been reported previously in patients with

CMT2A (11,12), it has always been in the context of a peripheral neuropathy where it is generally

considered to be a downstream consequence of nerve loss. For example, the MFN2 D210V variant has

myopathy phenotypes in a three-generational case study, which has accompanying axonal neuropathy

(10). On the other hand, arguing against the notion of muscle loss downstream of neuropathy,

mitochondrial myopathy is seen in a skeletal muscle-specific MFN2 loss-of-function study in animal

models, highlighting the importance of the protein in tissues such as skeletal muscle (70,71). Meanwhile,

in cardiac muscle, the MFN2 R400Q variant is implicated in cardiomyopathy, though no link to

inflammation was investigated (72). Additionally, the loss of MFN2 protein expression in skeletal muscles

correlates with age and could contribute to sarcopenia through a similar inflammatory mechanism (73).

Finally, similar to the patient we describe here, a novel ENU-induced Mfn2 mouse model characterized

L643P as a variant that causes muscle myopathy without peripheral neuropathy (74). Together, these

findings show that MFN2 dysfunction can cause muscle myopathy in the absence of nerve degeneration,

as observed in the proband. Future cases of myopathy associated with this variant in MFN2 may benefit

from the inclusion of electron microscopic examination of muscle biopsy tissues. EM was not obtained

for our case, but may have shown mitochondrial ultrastructural changes to provide further insight into

the morphological impacts of the MFN2 variant.

With respect to how MFN2 dysfunction might cause myopathy, in the first report of an MFN2-

specific mouse muscle knockout, the authors argued that the mtDNA depletion was likely a key

contributory factor due to reduced oxidative phosphorylation (70). However, more recent work linking

MFN1 and OPA1 muscle deficiency to inflammation mediated myopathy, showed that blocking the

inflammation was protective in these models (4,55), arguing for a key role of inflammation in the muscle

pathology caused by impaired mitochondrial fusion. Mechanistically, inflammation in the muscle cell

niche can lead to myopathy and interfere with muscle stem cell populations (75), as well as affect the

expression of myogenic genes (76). Meanwhile, NF-kB, a proinflammatory cytokine that is downstream

of TLR9 signaling, can cause muscle wasting in mice (77). Building on these findings, it is tempting to

speculate that mtDNA-mediated inflammation may also be relevant to idiopathic inflammatory

myopathies, a heterogeneous group of autoimmune disorders with varying clinical manifestations,

primarily defined by muscle weakness (78,79). In this regard, we speculate that the mtDNA-mediated

inflammation discovered in Q367H patient-derived cells is contributing to the patient myopathy.

Although MFN1 and OPA1 deficiency can cause inflammatory myopathy in mouse muscle

knockout models, the role of mtDNA-mediated inflammation in MFN2 pathology has not been fully

explored. While a mouse knock-in model of the MFN2 K357T variant is linked to augmented

neuroinflammation in response to LPS treatment, the role of mtDNA was not investigated (80). Our

findings linking the MFN2 Q367H variant to mtDNA release and inflammation thus provide a novel

disease mechanism for MFN2 dysfunction. Moreover, while our findings are relevant to the myopathy

phenotype in muscle, it is also possible that mtDNA-mediated inflammation contributes to the

peripheral neuropathy in neurons. Intriguingly, peripheral neuropathy is a common phenotype of several

DNA damaging agents (81–85), such as doxorubicin, which can damage mtDNA and lead to mtDNA-

mediated cGAS-STING inflammation (86).

In summary, we observed elevated mtDNA-mediated TLR9/NF-kB and cGAS-STING inflammatory

signaling in a patient harboring the uncharacterized MFN2 Q367H variant who displayed late-onset

myopathy as a standalone phenotype. Moreover, functional analyses of patient fibroblasts provided

several lines of evidence consistent with MFN2 dysfunction. Critically, characterization of

transdifferentiated myoblasts and the elucidation of a novel link to mtDNA-mediated inflammation may

mechanistically explain the myopathy phenotype in the patient.

Acknowledgements

The authors would like to thank the study participants and their family. Lentivirus production

was performed by the Hotchkiss Brain Institute Molecular Core Facility at the University of Calgary.

Conflict of Interests

The authors declare that they have no conflict of interest.

Author contributions

Designed and/or performed and analyzed mitochondrial experiments, MZ, GS, WA, TS, RS, MJ,

AM, CC GP, and TES; Clinical evaluation of patients, GP, JTJ; Analyzed exome data GP, MJ; Performed skin

biopsy from mitochondrial patients, GP; Drafted the manuscript or figures, MZ, GP, TES. All authors

discussed the results and commented on the manuscript. GS, and WA are joint second authors. TES and

GP are co-corresponding authors.

Funding

This work was supported by funds provided by the Alberta Children's Hospital Research Institute

(TES), the Canadian Institutes of Health Research (TES), and the New Frontiers Research Fund (TES). MZ

was supported by a Hotchkiss Brain Institute International Recruitment Scholarship. WA was supported

by the Saudi Cultural Bureau. R.S. was supported by a QEII Graduate Scholarship. TGBS was supported by

an Alberta Graduate Excellence Scholarship and a University of Calgary Faculty of Graduate Studies

Doctoral Scholarship. MJ is the recipient of the Katharine Sarah Melinda Mei-Ling Thomas Rare Diseases

Scholarship. Infrastructure in the lab of GP for this work was supported by the HBI Dementia Research

Equipment Fund and a Canada Foundation for Innovation JELF Grant (Neuromuscular Genetics, 36624).

The funders had no role in study design, data collection and interpretation, or the decision to submit the

work for publication.

Figure Legends:

Figure 1: Muscle pathology findings.

Representative images of the muscle biopsy (A-F) including two formalin-fixed, paraffin-embedded slides

(panels A and F) and four snap-frozen muscle sections (panels B-E). Distances are represented in the

scale bars. Panel A (hematoxylin-eosin; H&E) demonstrates extensive adipose tissue ("fatty

replacement") in the biopsy (black arrow). This was less obvious in the frozen tissue, which had been

dissected away from obvious fat. Panel B (H&E) illustrates the variation in myofiber size, as well as the

increased connective tissue between myofibers (endomysial fibrosis; green arrow). The biopsy had

several necrotic fibers (panel C H&E; black arrow) and increased numbers of internalized nuclei (black

arrowhead). In panel D (H&E) are two basophilic regenerating fibers (black arrows), internalized nuclei

(black arrowheads), and increased endomysial connective tissue (green arrow). Dystrophin

immunoperoxidase stains the myofiber sarcolemma (Dys2 illustrated in panel E). Dys1 and Dys3 are

similar (data not shown). The desmin immunoperoxidase in longitudinal sections (panel F) illustrates the

repetitive sarcolemmal units (stripes in each fiber) but does not stain significant sarcoplasmic deposits.

G. MRI image at the level of the legs demonstrating predominant atrophy in white arrows;

Gastrocnemius (i), Soleus (ii) and Tibialis Anterior (iii) bilaterally. H. MRI image of upper thighs

demonstrating predominant atrophy of adductor longus gluteus minimus.

Figure 2: Initial characterization of MFN2 Q367H variant.

A.(i) Sanger sequencing results showing single nucleotide polymorphism in patient fibroblasts, transition

Guanine to Cytosine. (ii) Topology diagram of MFN2 protein with domains and localization indicated. The

site of the Q367H variant is shown in the diagram. B. Amino acid sequence alignment using T-COFFEE

tool. C. Western Blot analysis comparing expression of mitochondrial fusion protein in control vs patient

fibroblasts, normalized to β-actin. (D-G) Comparison of protein expression levels (D) MFN2 (glucose

media) (E) MFN2 (glucose-free/galactose supplemented media) (F) MFN1 (G) OPA1 levels in control vs

patient fibroblasts. Data is indicative of mean +/- SD. Statistical comparisons were made by unpaired t-

test, (ns=not significant (p>0.05)).

Figure 3: Changes in mitochondrial morphology and respiratory function.

(A) Representative confocal images (top) with zoomed inset images (bottom) showing mitochondrial

network morphology in control vs patient fibroblasts stained with TOMM20. (B) Qualitative scoring of

proportion of cells showing fragmented/intermediate/fused mitochondrial network. Bars indicate mean

+/-SD. (C) Quantitative analysis of mean mitochondrial branch length in control vs patient fibroblasts

using glucose or glucose-free/galactose supplemented media, bars show mean +/- SD, colours indicate

biological replicates. (D) Oxygen Consumption Rate (OCR) assay on control and patient fibroblasts using

Seahorse XFe24, bars indicate mean +/- SD (n=12 replicates). Statistical comparisons were made by

unpaired t-test. (E) Mitochondrial Membrane potential is reported as mean fluorescent intensity IMFI) of

TMRE signal in live cells measured by flow cytometry. Bars indicate mean +/- SEM, points indicate

biological replicates, unpaired t-test. (ns=not significant ($p > 0.05$); ****=$p \leq 0.0001$).

Figure 4: Characterization of mtDNA nucleoids, mtDNA copy number, and mtDNA deletions.

(A) Representative confocal images showing mitochondria (TOMM20; grey) and mitochondrial nucleoids

(dsDNA antibody; red) in patient and control fibroblasts under glucose and glucose-free/galactose

supplemented nutrient conditions. Circles indicate presence of mtDNA nucleoids outside the

mitochondrial network. (B) Number of nucleoids per cell, mean is shown with colours indicating

biological replicates. (C) Average size of mitochondrial nucleoids, violin plots show median and

interquartile ranges. (D-E) qPCR data showing mitochondrial DNA copy number in (D) glucose and (E)

glucose-free/galactose supplemented media, bars indicate mean +/- SD. (F) Agarose gel electrophoresis

showing long range PCR products used to detect full-length or deleted mtDNA and DNA ladder showing

corresponding sizes. Statistical comparisons were made by unpaired t-test, (ns=not significant ($p > 0.05$);

*=$p \leq 0.05$; ***=$p \leq 0.001$; ****=$p \leq 0.0001$).

Figure 5: Mito-ER Contact site alterations.

(A) Representative confocal images of mito-ER contact sites (MERCs) using proximity ligation assay (PLA)

showing mitochondria (TOMM20; cyan), PLA probes (green) and ER (Calnexin; magenta) in glucose and

glucose-free/galactose supplemented media. (B) Quantitative analysis of number of MERCs per cell, lines

indicate mean +/- SD, colours indicate biological replicates. (C) Quantitative analysis of average size of

PLA probes, with violin plots indicate median and interquartile range. (D) Quantitative analysis of

mitochondrial area in each cell type in (μm^2), lines show mean +/- SD, colours indicate biological

replicates. (E) Normalized number of MERCs to total mitochondrial area per cell, lines indicate mean +/-

SD, colours indicate biological replicates. P-values determined by unpaired t-test (ns=not significant

($p > 0.05$); *=$p \leq 0.05$; **=$p \leq 0.01$; ****=$p \leq 0.0001$).

Figure 6: Changes to cellular lipid droplets.

(A-B) Representative confocal images showing lipid droplets stained with HCS LipidTox Green in (A)

glucose and (B) glucose-free/galactose supplemented media. (C) Quantitative analysis of the average

number of lipid droplets per cell, bars indicate mean +/- SD, colours indicate biological replicates. (D)

Quantitative analysis of the average size of lipid droplets, violin plots show median and interquartile

range. (E) Representative live-cell confocal images showing mitochondria (MitoTracker Green) and fatty

acids (BODIPY 558/568) at 0 hours and 24 hours in standard or glucose-starved media. (F) Quantitative

analysis of co-localization between fatty acid and mitochondrial network, colours indicate cell type (red-

control and blue-MFN2 Q367H), bars indicate mean +/- SD. P-values determined by unpaired t-test

(ns=not significant (p>0.05); **=p≤ 0.01; ****=p≤ 0.0001).

Figure 7: MFN2 Q367H cells show activation of TLR9 and cGAS-STING inflammatory pathways, and co-

localization of mtDNA with early endosomes.

(A) RT-qPCR data showing gene expression for TLR9/NF-KB targets (Asc, IL6, NLRP3, S100a9, TNF) and

cGAS-STING targets (Ifn-α, Ifn-β) in control vs patient fibroblasts under glucose conditions. The graph

also shows the effects of inhibitors for the TLR pathway (Chloroquine) or cGAS-STING pathway (RU.521).

Lines indicate mean +/- SD. (B) Representative confocal images showing mitochondria (TOMM20; cyan),

mitochondrial nucleoids (anti-dsDNA antibody; green), and early endosomes (RAB5C; magenta). Images

in inset bottom right panel highlights the location of mitochondrial nucleoids outside the mitochondria

with the early endosomes, denoted by the white arrows. (C) Quantitative analysis of signal co-

localization between mitochondrial nucleoids and early endosomes in patient and control fibroblasts

determined by Pearson's coefficient, lines indicate mean +/- SD, points indicate replicates. (D) Pathway

model representing mitochondrial dysfunction leading to sterile inflammation. The diagram shows how

the MFN2 Q367H variant can alter mitochondrial function, leading to transfer of mtDNA from the

mitochondria to the early endosomes (middle). This can lead to detection by TLR9 and subsequent

activation of the NF-kB mediated inflammation (right). Additionally, mtDNA in the early endosomes

could leak into the cytosol, leading to detection through the cGAS-STING pathway (middle-bottom),

promoting Type-I Interferon mediated inflammation (right). Collectively, the inflammation contributes to

the distal myopathy disease outcome in the patient. P-values determined by unpaired t-test (ns=not

significant (p>0.05); *=p≤ 0.05; ****=p≤ 0.0001).

Figure 8: Altered MFN2 functions in transdifferentiated patient myoblasts.

(A) RT-qPCR data showing gene expression for TLR9/NF-KB targets (Asc, IL6, NLRP3, S100a9, TNF) and

cGAS-STING targets (Ifn-α, Ifn-β) in control vs patient myoblasts, lines indicate mean +/- SD.(B)

Representative confocal images showing mitochondrial network morphology (TOMM20; cyan) in control

and patient myoblasts. (C) Quantitative analysis of mean mitochondrial branch length in control and

patient myoblasts, violin plots show median and interquartile ranges. (D) Representative confocal images

of control and patient myoblasts showing PLA probes (representing MERCs; green), mitochondria

(TOMM20; cyan) and ER (Calnexin; magenta). (E) Quantitative analysis of the number of MERCs per cell

in control and patient myoblasts, violin plots show media and interquartile ranges. (F) Quantitative

analysis of average size of MERCs per cell in control and patient myoblasts, violin plots show media and

interquartile ranges. (G) Representative confocal images showing mitochondria (TOMM20) and

mitochondrial nucleoids (dsDNA antibody). Circles indicate mtDNA staining outside the mitochondrial

network. (H) Quantification of average number of nucleoids per cell in control and patient myoblasts,

violin plots show median and interquartile ranges. (I) Quantification of average size of mtDNA nucleoids

in control and patient myoblasts. Violin plots show median and interquartile ranges. P-values

determined by unpaired t-test (ns=not significant ($p>0.05$); ***=$p \leq 0.001$; ****=$p \leq 0.0001$).

Figure 9: Re-Expression of WT MFN2 and MFN2 Q367H in knockout cells.

(A) Representative confocal images showing mitochondria (TOMM20-grey), mtDNA (dsDNA-green) and

early endosomes (Rab5-magenta) in U2OS WT, U2OS MFN2 KO, U2OS MFN2 KO cells with re-expression

of WT MFN2 and U2OS MFN2 KO cells with re-expression of Q367H MFN2 (left to right). Insets are of the

boxed regions in above pictures, dotted circles show mtDNA outside the mitochondrial network, while

arrows show mtDNA outside the mitochondrial network and co-localized with early endosomes. (B)

Western Blot analyses confirming re-expression of WT MFN2 and MFN2 Q367H in U2OS MFN2 KO cells.

(C) Quantitative analyses of mitochondrial network morphology in the four cell lines. (D) Quantitative

analyses of Pearson's Co-localization co-efficient between mtDNA and early endosomes in the four cell

lines. Colors indicate biological replicates; violins show median and interquartile range. Stats- two-way

ANOVA (ns=not significant ($p>0.05$); *=$p \leq 0.05$; **=$p \leq 0.01$; ****=$p \leq 0.0001$).

Supplemental Figure 1: Proximity Ligation Assay (PLA) validation.

(A) Pearson's co-localization analysis comparing overlap between PLA signals with mitochondria

(TOMM20) or ER (calnexin) in control and patient cells under glucose media. Violin plots indicate median

and interquartile range. Statistical analysis was performed via unpaired t-test.

Supplemental Figure 2: Inflammatory response in glucose-free media.

(A) RT-qPCR data showing gene expression for TLR9/NF-KB targets (Asc, IL6, NLRP3, S100a9, TNF) and

cGAS-STING pathway targets (INFα, INFβ) in control (CF) vs patient fibroblasts (Q367H) under glucose-

free media conditions. Colors indicate biological replicates. Error bars indicate mean +/- SD. Statistical

analysis was performed via unpaired t-test with the relevant control.

Supplemental Figure 3: Re-Expression of WT MFN2 and MFN2 Q367H in knockout cells.

Quantification of additional cellular phenotypes for the indicated cell lines from Figure 8. (A-D)

Characterization of mitochondrial DNA (mtDNA) including: (A) nucleoid copy number; (B) nucleoid size;

(C)average number of extra-mitochondrial nucleoids; (D) average number of extra-mitochondrial

nucleoids within Rab5-positive early endosomes (D); and (E) percentage of extra-mitochondrial

nucleoids within Rab5-positive endosomes (F-H) Quantification of Rab5-positive endosomes, including:

(F) average number of endosomes; (G) average endosome size; and (H) average distance between

mitochondria and endosomes. Colors indicate biological replicates, violin plots show median and

interquartile range, while error bars show mean +/- SD. P-values are all determined by two-way ANOVA,

(ns=not significant (p>0.05); *=p≤ 0.05; **=p≤ 0.01; ****=p≤ 0.0001).

References

1.   Filadi R, Pendin D, Pizzo P. Mitofusin 2: from functions to disease. Cell Death Dis. 2018 Feb
28;9(3):330.

2.   de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature.
2008 Dec 4;456(7222):605–10.

3.   Boutant M, Kulkarni SS, Joffraud M, Ratajczak J, Valera-Alberni M, Combe R, et al. Mfn2 is critical
for brown adipose tissue thermogenic function. EMBO J. 2017 Jun 1;36(11):1543–58.

4.   Irazoki A, Gordaliza-Alaguero I, Frank E, Giakoumakis NN, Seco J, Palacín M, et al. Disruption of
mitochondrial dynamics triggers muscle inflammation through interorganellar contacts and
mitochondrial DNA mislocation. Nat Commun. 2023 Jan 6;14(1):108.

5.   Zervopoulos SD, Boukouris AE, Saleme B, Haromy A, Tejay S, Sutendra G, et al. MFN2-driven
mitochondria-to-nucleus tethering allows a non-canonical nuclear entry pathway of the mitochondrial
pyruvate dehydrogenase complex. Mol Cell. 2022 Mar 3;82(5):1066-1077.e7.

6.   Li J, Dang X, Franco A, Dorn GW. Reciprocal Regulation of Mitofusin 2-Mediated Mitophagy and
Mitochondrial Fusion by Different PINK1 Phosphorylation Events. Front Cell Dev Biol. 2022;10:868465.

7.   McLelland GL, Goiran T, Yi W, Dorval G, Chen CX, Lauinger ND, et al. Mfn2 ubiquitination by
PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy. Dikic I,
editor. eLife. 2018 Apr 20;7:e32866.

8.   Sharma G, Pfeffer G, Shutt TE. Genetic Neuropathy Due to Impairments in Mitochondrial
Dynamics. Biology. 2021 Apr;10(4):268.

9.   Feely SME, Laura M, Siskind CE, Sottile S, Davis M, Gibbons VS, et al. MFN2 mutations cause
severe phenotypes in most patients with CMT2A. Neurology. 2011 May 17;76(20):1690–6.

10.   Rouzier C, Bannwarth S, Chaussenot A, Chevrollier A, Verschueren A, Bonello-Palot N, et al. The
MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy "plus" phenotype. Brain J
Neurol. 2012 Jan;135(Pt 1):23–34.

11.   Abati E, Manini A, Velardo D, Del Bo R, Napoli L, Rizzo F, et al. Clinical and genetic features of a
cohort of patients with MFN2-related neuropathy. Sci Rep. 2022 Apr 13;12(1):6181.

12.   Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, Ceuterick C, et al. MFN2 mutation
distribution and genotype/phenotype correlation in Charcot–Marie–Tooth type 2. Brain. 2006 Aug
1;129(8):2093–102.

13.   Sharma G, Zaman M, Sabouny R, Joel M, Martens K, Martino D, et al. Characterization of a novel
variant in the HR1 domain of MFN2 in a patient with ataxia, optic atrophy and sensorineural hearing loss.
F1000Research. 2022 Sep 2;10:606.

14.   Sawyer SL, Cheuk-Him Ng A, Innes AM, Wagner JD, Dyment DA, Tetreault M, et al. Homozygous
mutations in MFN2 cause multiple symmetric lipomatosis associated with neuropathy. Hum Mol Genet.
2015 Sep 15;24(18):5109–14.

15.   Mann JP, Duan X, Patel S, Tábara LC, Scurria F, Alvarez-Guaita A, et al. A mouse model of human
mitofusin-2-related lipodystrophy exhibits adipose-specific mitochondrial stress and reduced leptin
secretion. eLife. 2023 Feb 1;12:e82283.

16.   Masingue M, Vatier C, Jéru I, Latour P, Jardel C, Laforêt P, et al. Homozygous p.R707W MFN2
mutation is associated with neuropathy, lipomatosis, peripheral lipoatrophy and metabolic alterations.
Neuromuscul Disord. 2017 Oct 1;27:S148.

17.   Zaman M, Shutt TE. The Role of Impaired Mitochondrial Dynamics in MFN2-Mediated Pathology.
Front Cell Dev Biol. 2022;10:858286.

18.   Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, et al. Mitochondrial fusion is
required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell. 2010 Apr
16;141(2):280–9.

19.   Rodríguez-Nuevo A, Díaz-Ramos A, Noguera E, Díaz-Sáez F, Duran X, Muñoz JP, et al.
Mitochondrial DNA and TLR9 drive muscle inflammation upon Opa1 deficiency. EMBO J. 2018 May
15;37(10):e96553.

20.   Sidarala V, Zhu J, Levi-D'Ancona E, Pearson GL, Reck EC, Walker EM, et al. Mitofusin 1 and 2
regulation of mitochondrial DNA content is a critical determinant of glucose homeostasis. Nat Commun.
2022 Apr 29;13(1):2340.

21.   Vielhaber S, Debska-Vielhaber G, Peeva V, Schoeler S, Kudin AP, Minin I, et al. Mitofusin 2
mutations affect mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol (Berl). 2013
Feb;125(2):245–56.

22.   Newman LE, Shadel GS. Mitochondrial DNA Release in Innate Immune Signaling. Annu Rev
Biochem. 2023 Jun 20;92:299–332.

23.   VanPortfliet JJ, Chute C, Lei Y, Shutt TE, West AP. Mitochondrial DNA release and sensing in
innate immune responses. Hum Mol Genet. 2024 May 22;33(R1):R80–91.

24.   Al Khatib I, Deng J, Lei Y, Torres-Odio S, Rojas GR, Newman LE, et al. Activation of the cGAS-STING
innate immune response in cells with deficient mitochondrial topoisomerase TOP1MT. Hum Mol Genet.
2023 Jul 20;32(15):2422–40.

25.   Kim J, Kim HS, Chung JH. Molecular mechanisms of mitochondrial DNA release and activation of
the cGAS-STING pathway. Exp Mol Med. 2023 Mar;55(3):510–9.

26.   Pereira CA, Carlos D, Ferreira NS, Silva JF, Zanotto CZ, Zamboni DS, et al. Mitochondrial DNA
Promotes NLRP3 Inflammasome Activation and Contributes to Endothelial Dysfunction and Inflammation
in Type 1 Diabetes. Front Physiol. 2019;10:1557.

27.   Qiu Y, Huang Y, Chen M, Yang Y, Li X, Zhang W. Mitochondrial DNA in NLRP3 inflammasome
activation. Int Immunopharmacol. 2022 Jul;108:108719.

28.   Martens K, Leckie J, Fok D, Wells RA, Chhibber S, Pfeffer G. Case Report: Calpainopathy
Presenting After Bone Marrow Transplantation, With Studies of Donor Genetic Content in Various Tissue
Types. Front Neurol. 2020;11:604547.

29.   Griffin HR, Pyle A, Blakely EL, Alston CL, Duff J, Hudson G, et al. Accurate mitochondrial DNA
sequencing using off-target reads provides a single test to identify pathogenic point mutations. Genet
Med. 2014 Dec;16(12):962–71.

30.   Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang JM, et al. T-Coffee: a web
server for the multiple sequence alignment of protein and RNA sequences using structural information
and homology extension. Nucleic Acids Res. 2011 Jul;39(Web Server issue):W13-17.

31.   UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res.
2023 Jan 6;51(D1):D523–31.

32.   Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-
source platform for biological-image analysis. Nat Methods. 2012 Jun 28;9(7):676–82.

33.   Uddin GM, Lacroix R, Zaman M, Khatib IA, Rho JM, Kurrasch DM, et al. The Ketogenic Diet
Metabolite β-Hydroxybutyrate Promotes Mitochondrial Elongation via Deacetylation and Improves
Autism-like Behavior in Zebrafish. bioRxiv. 2022 Jan 1;2022.10.03.510695.

34.   Zhao T, Goedhart CM, Sam PN, Sabouny R, Lingrell S, Cornish AJ, et al. PISD is a mitochondrial
disease gene causing skeletal dysplasia, cataracts, and white matter changes. Life Sci Alliance. 2019
Apr;2(2):e201900353.

35.   Al Khatib I, Deng J, Symes A, Kerr M, Zhang H, Huang SYN, et al. Functional characterization of
two variants of mitochondrial topoisomerase TOP1MT that impact regulation of the mitochondrial
genome. J Biol Chem. 2022 Oct;298(10):102420.

36.   Valente AJ, Maddalena LA, Robb EL, Moradi F, Stuart JA. A simple ImageJ macro tool for
analyzing mitochondrial network morphology in mammalian cell culture. Acta Histochem. 2017
Apr;119(3):315–26.

37.   Bolte S, Cordelières FP. A guided tour into subcellular colocalization analysis in light microscopy. J
Microsc. 2006 Dec;224(Pt 3):213–32.

38.   Montava-Garriga L, Singh F, Ball G, Ganley IG. Semi-automated quantitation of mitophagy in cells
and tissues. Mech Ageing Dev. 2020 Jan;185:111196.

39.   Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, et al. Nesprin-1 and -2 are
involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope
integrity. Hum Mol Genet. 2007 Dec 1;16(23):2816–33.

40.   Beręsewicz M, Boratyńska-Jasińska A, Charzewski Ł, Kawalec M, Kabzińska D, Kochański A, et al.
The Effect of a Novel c.820C>T (Arg274Trp) Mutation in the Mitofusin 2 Gene on Fibroblast Metabolism
and Clinical Manifestation in a Patient. PloS One. 2017;12(1):e0169999.

41.   Sabouny R, Shutt TE. The role of mitochondrial dynamics in mtDNA maintenance. J Cell Sci. 2021
Dec 15;134(24):jcs258944.

42.   de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature.
2008 Dec 4;456(7222):605–10.

43.   Rambold AS, Cohen S, Lippincott-Schwartz J. Fatty acid trafficking in starved cells: regulation by
lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. Dev Cell. 2015 Mar 23;32(6):678–
92.

44.   Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S, et al. Chloroquine and
inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal
Physiol. 2008 May;294(5):F1050–8.

45.   Vincent J, Adura C, Gao P, Luz A, Lama L, Asano Y, et al. Small molecule inhibition of cGAS
reduces interferon expression in primary macrophages from autoimmune mice. Nat Commun. 2017 Sep
29;8(1):750.

46.   Huang P, Yu T, Yoon Y. Mitochondrial clustering induced by overexpression of the mitochondrial
fusion protein Mfn2 causes mitochondrial dysfunction and cell death. Eur J Cell Biol. 2007 Jun;86(6):289–
302.

47.   Pipis M, Feely SME, Polke JM, Skorupinska M, Perez L, Shy RR, et al. Natural history of Charcot-
Marie-Tooth disease type 2A: a large international multicentre study. Brain J Neurol. 2020 Dec
1;143(12):3589–602.

48.   Xie Y, Li X, Liu L, Hu Z, Huang S, Zhan Y, et al. MFN2-related genetic and clinical features in a
cohort of Chinese CMT2 patients. J Peripher Nerv Syst JPNS. 2016 Mar;21(1):38–44.

49.   Tarailo-Graovac M, Zhu JYA, Matthews A, van Karnebeek CDM, Wasserman WW. Assessment of
the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe
Mendelian pediatric disorders. Genet Med Off J Am Coll Med Genet. 2017 Dec;19(12):1300–8.

50.   Almomen M, Martens K, Quadir A, Pontifex CS, Hanson A, Korngut L, et al. High diagnostic yield
and novel variants in very late-onset spasticity. J Neurogenet. 2019 Mar;33(1):27–32.

51.   Sabouny R, Shutt TE. Reciprocal Regulation of Mitochondrial Fission and Fusion. Trends Biochem
Sci. 2020 Jul;45(7):564–77.

52.   Filipe A, Chernorudskiy A, Arbogast S, Varone E, Villar-Quiles RN, Pozzer D, et al. Defective
endoplasmic reticulum-mitochondria contacts and bioenergetics in SEPN1-related myopathy. Cell Death
Differ. 2021 Jan;28(1):123.

53.   Larrea D, Pera M, Gonnelli A, Quintana-Cabrera R, Akman HO, Guardia-Laguarta C, et al. MFN2
mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do
not impair bioenergetics. Hum Mol Genet. 2019 Jun 1;28(11):1782–800.

54.   Boutant M, Kulkarni SS, Joffraud M, Ratajczak J, Valera-Alberni M, Combe R, et al. Mfn2 is critical
for brown adipose tissue thermogenic function. EMBO J. 2017 Jun 1;36(11):1543–58.

55.   Rodríguez-Nuevo A, Díaz-Ramos A, Noguera E, Díaz-Sáez F, Duran X, Muñoz JP, et al.
Mitochondrial DNA and TLR9 drive muscle inflammation upon Opa1 deficiency. EMBO J. 2018 May
15;37(10):e96553.

56. Wei FL, Wang TF, Wang CL, Zhang ZP, Zhao JW, Heng W, et al. Cytoplasmic Escape of
Mitochondrial DNA Mediated by Mfn2 Downregulation Promotes Microglial Activation via cGas-Sting
Axis in Spinal Cord Injury. Adv Sci Weinh Baden-Wurtt Ger. 2023 Nov 27;e2305442.

57. Zhou M, Cheng X, Zhu W, Jiang J, Zhu S, Wu X, et al. Activation of cGAS-STING pathway - A
possible cause of myofiber atrophy/necrosis in dermatomyositis and immune-mediated necrotizing
myopathy. J Clin Lab Anal. 2022 Oct;36(10):e24631.

58. Sen A, Boix J, Pla-Martín D. Endosomal-dependent mitophagy coordinates mitochondrial
nucleoid and mtDNA elimination. Autophagy. 19(9):2609–10.

59. Sen A, Kallabis S, Gaedke F, Jüngst C, Boix J, Nüchel J, et al. Mitochondrial membrane proteins
and VPS35 orchestrate selective removal of mtDNA. Nat Commun. 2022 Nov 7;13:6704.

60. Newman LE, Weiser Novak S, Rojas GR, Tadepalle N, Schiavon CR, Grotjahn DA, et al.
Mitochondrial DNA replication stress triggers a pro-inflammatory endosomal pathway of nucleoid
disposal. Nat Cell Biol. 2024 Feb;26(2):194–206.

61. Silva Ramos E, Motori E, Brüser C, Kühl I, Yeroslaviz A, Ruzzenente B, et al. Mitochondrial fusion
is required for regulation of mitochondrial DNA replication. PLoS Genet. 2019 Jun;15(6):e1008085.

62. Ilamathi HS, Benhammouda S, Lounas A, Al-Naemi K, Desrochers-Goyette J, Lines MA, et al.
Contact sites between endoplasmic reticulum sheets and mitochondria regulate mitochondrial DNA
replication and segregation. iScience. 2023 Jul 21;26(7):107180.

63. Lewis SC, Uchiyama LF, Nunnari J. ER-mitochondria contacts couple mtDNA synthesis with
mitochondrial division in human cells. Science. 2016 Jul 15;353(6296):aaf5549.

64. Tur J, Pereira-Lopes S, Vico T, Marín EA, Muñoz JP, Hernández-Alvarez M, et al. Mitofusin 2 in
Macrophages Links Mitochondrial ROS Production, Cytokine Release, Phagocytosis, Autophagy, and
Bactericidal Activity. Cell Rep. 2020 Aug 25;32(8):108079.

65. Liu H, Liu X, Zhuang H, Fan H, Zhu D, Xu Y, et al. Mitochondrial Contact Sites in Inflammation-
Induced Cardiovascular Disease. Front Cell Dev Biol. 2020 Jul 30;8:692.

66. Akhmetova K, Balasov M, Chesnokov I. Drosophila STING protein has a role in lipid metabolism.
eLife. 2021 Sep 1;10:e67358.

67. Bai J, Cervantes C, He S, He J, Plasko GR, Wen J, et al. Mitochondrial stress-activated cGAS-STING
pathway inhibits thermogenic program and contributes to overnutrition-induced obesity in mice.
Commun Biol. 2020 May 22;3(1):257.

68. Monson EA, Crosse KM, Das M, Helbig KJ. Lipid droplet density alters the early innate immune
response to viral infection. Zhang L, editor. PLOS ONE. 2018 Jan 2;13(1):e0190597.

69. Boucher DM, Vijithakumar V, Ouimet M. Lipid Droplets as Regulators of Metabolism and
Immunity. Immunometabolism [Internet]. 2021 Jul [cited 2024 Feb 19];3(3). Available from:
https://journals.lww.com/10.20900/immunometab20210021

70. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, et al. Mitochondrial fusion is
required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell. 2010 Apr
16;141(2):280–9.

71. Chen Z, Bordieanu B, Kesavan R, Lesner NP, Venigalla SSK, Shelton SD, et al. Lactate metabolism
is essential in early-onset mitochondrial myopathy. Sci Adv. 2023 Jan 4;9(1):eadd3216.

72. Franco A, Li J, Kelly DP, Hershberger RE, Marian AJ, Lewis RM, et al. A human mitofusin 2
mutation can cause mitophagic cardiomyopathy. eLife. 2023 Nov 1;12:e84235.

73. Sebastián D, Sorianello E, Segalés J, Irazoki A, Ruiz-Bonilla V, Sala D, et al. Mfn2 deficiency links
age-related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway. EMBO
J. 2016 Aug 1;35(15):1677–93.

74. Hines TJ, Bailey J, Liu H, Guntur AR, Seburn KL, Pratt SL, et al. A Novel ENU-Induced Mfn2
Mutation Causes Motor Deficits in Mice without Causing Peripheral Neuropathy. Biology. 2023 Jul
3;12(7):953.

75. Perandini LA, Chimin P, Lutkemeyer D da S, Câmara NOS. Chronic inflammation in skeletal muscle
impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche?
FEBS J. 2018 Jun;285(11):1973–84.

76. Chandran R, Knobloch TJ, Anghelina M, Agarwal S. Biomechanical signals upregulate myogenic
gene induction in the presence or absence of inflammation. Am J Physiol Cell Physiol. 2007
Jul;293(1):C267-276.

77. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HGW, et al. IKKbeta/NF-kappaB activation
causes severe muscle wasting in mice. Cell. 2004 Oct 15;119(2):285–98.

78. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al.
Idiopathic inflammatory myopathies. Nat Rev Dis Primer. 2021 Dec 2;7(1):86.

79. Silva AMS, Campos ED, Zanoteli E. Inflammatory myopathies: an update for neurologists. Arq
Neuropsiquiatr. 2022 May;80(5 Suppl 1):238–48.

80. Stavropoulos F, Sargiannidou I, Potamiti L, Kagiava A, Panayiotidis MI, Bae JH, et al. Aberrant
Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of
CMT2A. Int J Mol Sci. 2021 Oct 26;22(21):11569.

81. Kerckhove N, Pezet D, Balayssac D. Long-Term Effects, Pathophysiological Mechanisms, and Risk
Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front
Pharmacol [Internet]. 2017 Feb 24 [cited 2024 Mar 12];8. Available from:
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00086/full

82. Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated Peripheral
Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. JNCI J Natl Cancer Inst.
2018 Feb 1;110(2):djx140.

83. Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, et al. Drug-Induced Peripheral
Neuropathy: A Narrative Review. Curr Clin Pharmacol. 2020 Apr;15(1):38.

84.   Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and
targeted agents: diagnosis, treatment, and prevention. Neuro-Oncol. 2012 Sep;14(Suppl 4):iv45–54.

85.   Cella D, Huang H, Homesley HD, Montag A, Salani R, De Geest K, et al. Patient-reported
peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of
advanced endometrial cancer: Results from GOG 184. Gynecol Oncol. 2010 Dec;119(3):538–42.

86.   Wu Z, Oeck S, West AP, Mangalhara KC, Sainz AG, Newman LE, et al. Mitochondrial DNA Stress
Signalling Protects the Nuclear Genome. Nat Metab. 2019 Dec;1(12):1209–18.

1083

A. (i) Part of Exon 11 in MFN2 gene

Homo sapiens chromosome 1, GRCh38.p13 (Source: NCBI)

NCBI MFN2

Patient fibroblast

CAG: Glutamine (Q)
CAC: Histidine(H)

Control fibroblast

A. (ii)

B.

C.

D.

E.

F.

G.

A.

B.

Control Fibroblasts   MFN2 Q367H

Mitochondria
dsDNA

Early Endosomes

Merge

Inset

C.

D.

A.

	U2OS WT	U2OS MFN2 KO	MFN2 KO + WT MFN2	MFN2 KO + MFN2 Q367H

Mito dsDNA E. Endosomes

Inset

B.

	WT MFN2	MFN2 KO	MFN2 KO + WT MFN2	MFN2 KO + Q367H MFN2

MFN2

Beta Actin

C.

Mitochondrial Network Morphology

Mean Mitochondrial Branch Length (μm)

ns

****

****

U2OS WT   U2OS MFN2 KO   MFN2 KO + WT MFN2   MFN2 KO + MFN2 Q367H

D.

Pearson Co-Localization

Pearson's Co-localization Coefficient (mtDNA:Rab5+ Endosomes)

****

****

ns

U2OS WT   U2OS MFN2 KO   MFN2 KO + WT MFN2   MFN2 KO + MFN2 Q367H

Gene	Disease/ Inheritance pattern	Coding variant	Amino acid change	rsID	Max reported MAF	ClinVar	Zygosity	Polyphen 2 prediction	Mutation-taster prediction
MFN2	CMT neuropathy 2A; AD	c.1101G>C	p.Gln367His	rs373211062	0.00024	VUS, conflicting interpretations	Hetero-zygous	B	D
DYSF	LGMD 2B; AR	c.5180G>C	p.Gly1727Ala	rs146153532	1.16E-04	VUS	Hetero-zygous	P	D
SYNE1	EDMD 4; AD/AR	c.9934G>A	p.Asp3312Asn	rs147281213	2.33E-04	VUS	Hetero-zygous	D	D

AD=autosomal dominant; AR=autosomal recessive; B= benign; CMT=Charcot Marie Tooth; D=deleterious; EDMD=Emery Dreyfuss muscular dystrophy; LGMD=limb girdle muscular dystrophy; MAF=minor allele frequency; P=possibly tolerated; VUS=variant of uncertain significance.